TABLE 1.
Baseline characteristics and post‐transplant outcomes among kidney transplant recipients with prior COVID‐19
| COVID+ (n = 13) | COVID‐ (n = 68) | P‐value | |
|---|---|---|---|
| Baseline Characteristics | |||
| Recipient Age, years | 52.8 ± 13.0 | 53.6 ± 12.7 | 0.85 |
| Gender | 0.15 | ||
| Male | 11 (84.6%) | 44 (64.7%) | |
| Female | 2 (15.4%) | 24 (35.3%) | |
| Recipient BMI, kg/m2 | 28.4 ± 6.3 | 25.6 ± 5.1 | 0.18 |
| Ethnicity | |||
| White/European | 1 (7.7%) | 19 (27.9%) | 0.12 |
| Black/African‐American | 4 (30.8%) | 26 (38.2%) | 0.62 |
| Hispanic/Latino | 7 (53.8%) | 12 (17.6%) | <0.01 |
| Asian/Pacific Islander | 1 (7.7%) | 11 (16.2%) | 0.44 |
| Etiology of ESKD | 0.77 | ||
| Hypertension | 5 (38.5%) | 22 (32.4%) | |
| Diabetes Mellitus | 4 (30.8%) | 14 (20.6%) | |
| Glomerulonephritis | 3 (23.1%) | 18 (26.5%) | |
| Polycystic Kidney Disease | 0 (0.0%) | 3 (4.4%) | |
| Other | 1 (7.7%) | 11 (16.2%) | |
| Median Duration of Dialysis, years | 3 (1‐10.5) | 4.5 (1‐8) | 0.82 |
| Prior Transplantation | 2 (15.4%) | 9 (13.2%) | 0.83 |
| Comorbidities | |||
| Hypertension | 13 (100.0%) | 61 (89.7%) | 0.23 |
| Diabetes Mellitus | 6 (46.2%) | 23 (33.8%) | 0.40 |
| HIV | 2 (15.4%) | 10 (14.7%) | 0.93 |
| Donor Source | 0.40 | ||
| Living Donor | 3 (23.1%) | 24 (35.3%) | |
| Deceased Donor | 10 (76.9%) | 44 (64.7%) | |
| Median CIT, hours | 14 (11.5‐19) | 11 (1‐22) | 0.42 |
| Positive B‐cell Crossmatch | 0 (0.0%) | 11 (16.2%) | 0.12 |
| Post‐Transplant Outcomes | |||
| Patient Survival a | 12 (92.3%) | 68 (100.0%) | 0.16 |
| Allograft Survival a | 12 (92.3%) | 67 (98.5%) | 0.29 |
| Serum Creatinine at 1‐month | 1.48 ± 0.44 | 1.49 ± 0.74 | 0.93 |
| Urine Protein Dipstick > 100 mg/dL at 1‐month | 1 (7.7%) | 3 (4.4%) | 0.61 |
| Surgical Complications | |||
| Unplanned Re‐operation | 0 (0.0%) | 3 (4.4%) | 0.43 |
| Failed Extubation in OR/PACU | 2 (15.4%) | 1 (1.5%) | 0.02 |
| Delayed Allograft Function | 4 (30.8%) | 15 (22.1%) | 0.47 |
| Median Index Hospital Length of Stay, days | 5 (3.5‐6.5) | 4 (4‐6) | 0.74 |
| Hospital Readmission within 30‐days | 3 (23.1%) | 24 (35.3%) | 0.39 |
a
Median follow‐up = 3.6 months
This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency.